Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$735.64 USD

735.64
703,572

+10.77 (1.49%)

Updated Apr 26, 2024 11:51 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (198 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie

Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.

Sweta Killa headshot

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Kinjel Shah headshot

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eli Lilly (LLY) Advances But Underperforms Market: Key Facts

Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.

Company News for Apr 18, 2024

Companies In The Article are: LLY,ADSK,MBLY,USB

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.

The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo

Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo are included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for Eli Lilly, Linde & Caterpillar

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN) and Caterpillar Inc. (CAT).

Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Eli Lilly (LLY) stood at $749.26, denoting a -0.2% change from the preceding trading day.

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Eli Lilly (LLY) Increases Despite Market Slip: Here's What You Need to Know

Eli Lilly (LLY) reachead $761.98 at the closing of the latest trading day, reflecting a +0.63% change compared to its last close.

Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up

Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.

Neena Mishra headshot

Healthcare ETFs for the Weight-Loss Drug Boom & Beyond

We discuss attractive investment opportunities within the healthcare industry.

Zacks Market Edge Highlights: VICI Properties, KeyCorp, Meta Platforms, ExxonMobil and Eli Lilly

ICI Properties, KeyCorp, Meta Platforms, ExxonMobil and Eli Lilly are part of the Zacks Market Edge blog.

Tracey Ryniec headshot

How to Create a Stock Portfolio that Pays $100 a Month

Forget buying a CD. Here's how to set yourself up with individual stocks that will net you passive income.